Probiotics for Treatment and Prevention of Urogenital Infections in Women: A Systematic Review

Journal of Midwifery and Women's Health

Volumn 61, Issue 3, 2016, Pages 339-355

  Hanson, Lisa ^a,b   Vandevusse, Leona ^a   Jermé, Martha ^c   Abad, Cybéle L ^d   Safdar, Nasia ^e,f  

^a MARQUETTE UNIVERSITY   (United States)

^b Aurora Midwifery and Wellness Center   (United States)

^c MARQUETTE UNIVERSITY   (United States)

^d UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

Infections; Probiotics; Systematic review; Urogenital; Women's health

Indexed keywords

ACETIC ACID; ARABINOGALACTAN; ASCORBIC ACID; BICARBONATE; CITRIC ACID; CLINDAMYCIN; CLOTRIMAZOLE; COTRIMOXAZOLE; FLUCONAZOLE; FRUCTOSE OLIGOSACCHARIDE; MAGNESIUM STEARATE; METRONIDAZOLE; PROBIOTIC AGENT; STEARIC ACID; TINIDAZOLE;

ABSENCE OF SIDE EFFECTS; ARTICLE; DRUG EFFICACY; FOLLOW UP; HUMAN; LACTOBACILLUS; META ANALYSIS (TOPIC); PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; URINARY TRACT INFECTION; UROGENITAL TRACT INFECTION; VAGINA CANDIDIASIS; VAGINITIS; CANDIDIASIS, VULVOVAGINAL; FEMALE; PAPILLOMAVIRUS INFECTIONS; URINARY TRACT INFECTIONS; VAGINOSIS, BACTERIAL;

CANDIDIASIS, VULVOVAGINAL; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PROBIOTICS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; VAGINOSIS, BACTERIAL;

EID: 84969916859     PISSN: 15269523     EISSN: 15422011     Source Type: Journal    
DOI: 10.1111/jmwh.12472     Document Type: Article

References (46)

1. Friedman CR, Whitney CG. It's time for a change in practice: reducing antibiotic use can alter antibiotic resistance. J Infect Dis. 2008;197:1082-1083.
2. Centers for Disease Control & Prevention [CDC]. 2015 Sexually Transmitted Diseases Treatment Guidelines-Bacterial Vaginosis. Atlanta, GA: Centers for Disease Control & Prevention; 2015, June 4. http://www.cdc.gov/std/tg2015/bv.htm Accessed August 15, 2015.
3. Ehrstrom S, Daroczy K, Rylander E, et al. Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microb Infect. 2010;12:691-699.
4. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193:1478-1489.
5. Centers for Disease Control & Prevention [CDC]. 2015 Sexually Transmitted Diseases Treatment Guidelines-Vulvovaginal Candidiasis. Atlanta, GA: Centers for Disease Control & Prevention; 2015, June 4. http://www.cdc.gov/std/tg2015/candidiasis.htm. Accessed August 30, 2015.
6. Hooton TM, Gupta K. Acute uncomplicated cystitis and pyelonephritis in women. In: Calderwood SB, ed. UpToDate. Waltham, MA: Wolters Kluwer; 2015. http://www.uptodate.com/contents/acute-uncomplicated-cystitis-and-pyelonephritis-in-women?source=search_result&search=Hooton+TM%2C+Gupta+K.+Acute+uncomplicated+cystitis+and+pyelonephritis+in+women.&selectedTitle=1%7E150. Accessed August 31, 2015.
7. Castle PE. The life cycle, natural history, and immunology of human papillomaviruses. In: Hirsch MS, ed. UpToDate. Waltham, MA: Wolters Kluwer; 2015. http://www.uptodate.com/contents/the-life-cycle-natural-history-and-immunology-of-human-papillomaviruses?source=search_result&search=Castle+PE.++The+life+cycle%2C+natural+history%2C+and+immunology+of+human+papillomaviruses. Accessed August 31, 2015.
8. Bolton M, Van Der Straten A, Cohen CR. Probiotics: potential to prevent HIV and sexually transmitted infections in women. Sex Transm Infect. 2008;35(3):214-225.
9. Donders GG. Microscopy of the bacterial flora on fresh vaginal smears. Infect Dis Obstet Gynecol. 1999;7:177-179.
10. Reid G, Dols J, Miller W. Targeting the vaginal microbiota with probiotics as a means to counteract infections. Curr Opin Clin Nutr Metab Care. 2009;12(6):583-587.
11. FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada: Author; April-May 2002. http://www.fda.gov/ohrms/dockets/dockets/95s0316/95s-0316-rpt0282-tab-03-ref-19-joint-faowho-vol219.pdf. Accessed July 4, 2015.
12. Abad CL, Safdar N. The role of Lactobacillus probiotics in the treatment or prevention of urogenital infections: A systematic review. J Chemother. 2009;21(3):243-252.
13. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. PLoS Med. 2009;6(7):e1000097.
14. Hemmerling A, Harrison W, Schroeder A, et al. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm Dis. 2010;37(12):745-750.
15. Mastromarino P, Macchia S, Meggiorini L, et al. Effectiveness of lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin Microbiol Infec. 2009;15(1):67-74.
16. Hemalatha R, Mastromarino P, Ramalaxmi BA, Balakrishna NV, Sesikeran B. Effectiveness of vaginal tablets containing lactobacilli versus pH tablets on vaginal health and inflammatory cytokines: A randomized, double-blind study. Eur J Clin Microbiol Infect Dis. 2012;31:3097-3105.
17. Petricevic L, Witt A. The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after antibiotic treatment of bacterial vaginosis. Br J Obstet Gynaecol. 2008;115(11):1369-1374.
18. Larsson P-G, Stray-Pedersen B, Ryttig KR, Larsen S. Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate: a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health. 2008;8(3):[8].
19. Martinez RCR, Franceschini SA, Patta MC, et al. Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial. Can J Microbiol. 2009;55:133-138.
20. Ya W, Reifer C, Miller LE. Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study. Am J Obstet Gynecol. 2010;203(2):120e1-120e6.
21. Donders GGG, Bulck B, Van de Walle P, et al. Effect of lyophilized lactobacilli and 0.03 mg estriol (Gynoflor®) on vaginitis and vaginosis with disrupted vaginal microflora: a multicenter, randomized, single-blind, active-controlled pilot study. Gynecol Obstet Invest. 2010;70(4), 264-272.
22. Bradshaw CS, Pirotta M, de Guingand D, et al. Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial. PLoS ONE. 2012;7(4):e34540.
23. Vicariotto F, Mogna L, Del Piano M. Effectiveness of the two microorganisms Lactobacillus fermentum LF15 and Lactobacillus plantarum LP01, formulated in slow-release vaginal tablets, in women affected by bacterial vaginosis: a pilot study. J Clin Gastroenterol. 2014;48:S106-S112.
24. Anukam KC, Duru MU, Eze CC, et al. Oral use of probiotics as an adjunctive therapy to fluconazole in the treatment of yeast vaginitis: a study of Nigerian women in an outdoor clinic. Microb Ecol Health D. 2009;21(2):72-77.
25. Beerepoot MAJ, Ter Riet G, Nys S, et al. Lactobacilli versus antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med. 2012;172(9):704-712.
26. Stapleton AE, Au-Young M, Hooton TM, et al. Randomized, placebo-controlled Phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for the prevention of recurrent urinary tract infection. CID. 2011;52(10): 1212-1217.
27. Verhoeven V, Renard N, Makar A, et al. Probiotics enhance the clearance of human papillomavirus-related cervical lesions: a prospective controlled pilot study. Eur J Cancer Prev. 2013;22(1):46-51.
28. Marcone V, Calzolari E, Bertini M. Effectiveness of vaginal administration of Lactobacillus rhamnosus following conventional metronidazole therapy: how to lower the rate of bacterial vaginosis recurrences. New Microbiol. 2008;31(3):429-433.
29. Ling Z, Liu X, Chen W, et al. The restoration of the vaginal microbiota after treatment for bacterial vaginosis with metronidazole or probiotics. Microb Ecol. 2013;65(3):773-780.
30. Rossi A, Rossi T, Bertini M, Caccia G. The use of Lactobacillus rhamnosus in the therapy of bacterial vaginosis: evaluation of clinical efficacy in a population of 40 women treated for 24 months. Arch Gynecol Obstet. 2010;281:1065-1069.
31. Vicariotto F, Del Piano M, Mogna L, Mogna G. Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study. J Clin Gastroenterol. 2012;46:S73-S80.
32. Murina F, Graziottin A, Vicariotto F, De Seta F. Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a slow-release vaginal product be useful for prevention of recurrent vulvovaginal candidiasis? A clinical study. J Clin Gastroenterol. 2014;48(Suppl.1):S102-S105.
33. Likis FE, Andrews JC, Collins MR, et al. Nitrous oxide for the management of labor pain. Comparative Effectiveness Review No. 67. AHRQ Publication No. 12-EHC071-EF. Rockville MD: Agency for Healthcare Research and Quality; 2012. Website www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed December 15, 2015.
34. Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomized trials. BMJ. 2011;343:d5928.
35. Agency for Healthcare Research and Quality (AHRQ). Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: AHRQ; 2008-2011. http://www.ncbi.nlm.nih.gov/books/NBK47095/. Accessed September 1, 2015.
36. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74:14-22.
37. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29:297-301.
38. Senok AC, Verstraelen H, TemmermanM, Botta GA. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev. 2009;4:CD006289.
39. Reid G, Charbonneau D, Erb J, et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. Fems Immunol Med Mic. 2003;35(2):131-134.
40. Andreu A. Lactobacillus as a probiotic for preventing urogenital infections. Rev Med Microbiol. 2004;15:1-6.
41. Huang H, Song L, Zhao W. Effects of probiotics for the treatment of bacterial vaginosis in adult women: a meta-analysis of randomized clinical trials. Arch Gynecol Obstet. 2014;289(6):1225-1234.
42. Jaisamrarn U, Castellsagué X, Garland SM, et al. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA Study. PLoS One. 2013;8(11):e79260.
43. Woo YL, van den Hende M, Sterling JC, Colema N. A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. Int J Cancer. 2010;126:133-141.
44. Elias J, Bozzo P, Einarson A. Are probiotics safe for use during pregnancy and lactation? Can Fam Phys. 2011;57:299-301.
45. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis. 2001;1:101-114.
46. Boyanova L, Mitov I. Coadministration of probiotics with antibiotics: why, when and for how long? Expert Rev Anti Infect Ther. 2012;10(4):407-409. http://www.ncbi.nlm.nih.gov/pubmed/22512748. Accessed September 1, 2015.